Skip to main content

CCL11 (Eotaxin-1) Levels Predict Long-Term Functional Outcomes in Patients Following Ischemic Stroke

Translational Stroke Research volume 8, pages 578–584 (2017)Cite this article

Abstract

Circulating levels of the pro-inflammatory cytokine C-C motif chemokine 11 (CCL11, also known as eotaxin-1) are increased in several animal models of neuroinflammation, including traumatic brain injury and Alzheimer’s disease. Increased levels of CCL11 have also been linked to decreased neurogenesis in mice. We hypothesized that circulating CCL11 levels would increase following ischemic stroke in mice and humans, and that higher CCL11 levels would correlate with poor long-term recovery in patients. As predicted, circulating levels of CCL11 in both young and aged mice increased significantly 24 h after experimental stroke. However, ischemic stroke patients showed decreased CCL11 levels compared to controls 24 h after stroke. Interestingly, lower post-stroke CCL11 levels were predictive of increased stroke severity and independently predictive of poorer functional outcomes in patients 12 months after ischemic stroke. These results illustrate important differences in the peripheral inflammatory response to ischemic stroke between mice and human patients. In addition, it suggests CCL11 as a candidate biomarker for the prediction of acute and long-term functional outcomes in ischemic stroke patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Rothenberg ME, Maclean JA, Pearlman E, Luster AD, Leder P. Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J Exp Med. 1997;185(4):785–90.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. Emanuele E, Falcone C, D’angelo A. Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. Atherosclerosis. 2006;186(1):140–5.

    CAS  Article  PubMed  Google Scholar 

  3. Mir A, Minguez M, Tatay J, et al. Elevated serum eotaxin levels in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97(6):1452–7.

    CAS  Article  PubMed  Google Scholar 

  4. Fryer AD, Stein LH, Nie Z, et al. Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. J Clin Invest. 2006;116(1):228–36.

    CAS  Article  PubMed  Google Scholar 

  5. Adar T, Shteingart S, Ben Ya’acov A, Bar-gil Shitrit A, Goldin E. From airway inflammation to inflammatory bowel disease: eotaxin-1, a key regulator of intestinal inflammation. Clin Immunol. 2014;153(1):199–208.

    CAS  Article  PubMed  Google Scholar 

  6. Targowski T, Jahnz-rózyk K, Plusa T, Glodzinska-wyszogrodzka E. Influence of age and gender on serum eotaxin concentration in healthy and allergic people. J Investig Allergol Clin Immunol. 2005;15(4):277–82.

    CAS  PubMed  Google Scholar 

  7. Villeda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477(7362):90–4.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. Shein SL, Shellington DK, Exo JL, et al. Hemorrhagic shock shifts the serum cytokine profile from pro- to anti-inflammatory after experimental traumatic brain injury in mice. J Neurotrauma. 2014;31(16):1386–95.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Manwani B, Liu F, Xu Y, Persky R, Li J, Mccullough LD. Functional recovery in aging mice after experimental stroke. Brain Behav Immun. 2011;25(8):1689–700.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Zschaler J, Schlorke D, Arnhold J. Differences in innate immune response between man and mouse. Crit Rev Immunol. 2014;34(5):433–54.

    CAS  PubMed  Google Scholar 

  11. Manwani B, Friedler B, Verma R, Venna VR, Mccullough LD, Liu F. Perfusion of ischemic brain in young and aged animals: a laser speckle flowmetry study. Stroke. 2014;45(2):571–8.

    Article  PubMed  Google Scholar 

  12. Flurkey K, Currer JM, Harrison DE. The mouse in aging research. In: Fox JG, editor. The mouse in biomedical research. 2nd ed. Burlington: College Laboratory Animal Medicine (Elsevier); 2007. p. 637–72.

    Chapter  Google Scholar 

  13. Huber AK, Giles DA, Segal BM, Irani DN. An emerging role for eotaxins in neurodegenerative disease. Clin Immunol. 2016.

  14. Menzies-gow A, Ying S, Sabroe I, et al. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol. 2002;169(5):2712–8.

    CAS  Article  PubMed  Google Scholar 

  15. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science. 1997;277(5334):2005–7.

    CAS  Article  PubMed  Google Scholar 

  16. De Paulis A, Annunziato F, Di Gioia L, et al. Expression of the chemokine receptor CCR3 on human mast cells. Int Arch Allergy Immunol. 2001;124(1–3):146–50.

    CAS  PubMed  Google Scholar 

  17. Erickson MA, Morofuji Y, Owen JB, Banks WA. Rapid transport of CCL11 across the blood-brain barrier: regional variation and importance of blood cells. J Pharmacol Exp Ther. 2014;349(3):497–507.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Parajuli B, Horiuchi H, Mizuno T, Takeuchi H, Suzumura A. CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia. Glia. 2015;63(12):2274–84.

    Article  PubMed  Google Scholar 

  19. Di Battista AP, Rhind SG, Hutchison MG, et al. Inflammatory cytokine and chemokine profiles are associated with patient outcome and the hyperadrenergic state following acute brain injury. J Neuroinflammation. 2016;13(1):40.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Kitaura M, Nakajima T, Imai T, et al. Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J Biol Chem. 1996;271(13):7725–30.

    CAS  Article  PubMed  Google Scholar 

  21. Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer’s disease brains. Am J Pathol. 1998;153(1):31–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  22. Chung KF, Patel HJ, Fadlon EJ, et al. Induction of eotaxin expression and release from human airway smooth muscle cells by IL-1beta and TNFalpha: effects of IL-10 and corticosteroids. Br J Pharmacol. 1999;127(5):1145–50.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. Garcia-zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med. 1996;2(4):449–56.

    CAS  Article  PubMed  Google Scholar 

  24. Gerber BO, Zanni MP, Uguccioni M, et al. Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr Biol. 1997;7(11):836–43.

    CAS  Article  PubMed  Google Scholar 

  25. Miyamasu M, Misaki Y, Yamaguchi M, et al. Regulation of human eotaxin generation by Th1-/Th2-derived cytokines. Int Arch Allergy Immunol. 2000;122(Suppl 1):54–8.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was funded by the National Institutes of Health NS094543 and NS076293 (to LDM), the Hartford Hospital Research Department, and the Russell and Diana Hawkins Family Foundation Discovery Fellowships to the Graduate School at UTHealth (to MAR) and the National Institutes of Health 1F30NS098628 (to MAR).

Author information

Affiliations

  1. Department of Neurology, University of Texas Health Science Center, Houston, TX, 77030, USA

    Meaghan Roy-O’Reilly & Louise D. McCullough

  2. Department of Neuroscience, University of Connecticut Health Center, Farmington, CT, 06032, USA

    Rodney M. Ritzel

  3. Department of Medicine, Brigham and Women’s Hospital, Boston, MA, 02115, USA

    Sarah E. Conway

  4. Hartford Hospital, 80 Seymour Street, Hartford, CT, 06106, USA

    Sarah E. Conway, Ilene Staff, Gilbert Fortunato & Louise D. McCullough

Authors
  1. Meaghan Roy-O’Reilly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rodney M. Ritzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah E. Conway
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ilene Staff
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gilbert Fortunato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Louise D. McCullough
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Louise D. McCullough.

Ethics declarations

Ethical Approval

All sample collection performed in studies involving human participants were conducted in accordance with the ethical standards of the Institutional Review Board at Hartford Hospital and the University of Connecticut Health Center and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

All applicable international, national, and institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted. All animal procedures were performed in accordance with the NIH guidelines for the care and use of laboratory animals and approved by the Animal Care Committee of the University of Connecticut Health Center.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Funding

This study was funded by the National Institutes of Health NS094543 and NS076293 (to LDM) and the Hartford Hospital Research Department, and the Russell and Diana Hawkins Family Foundation Discovery Fellowships to the Graduate School at UTHealth (to MAR) and the National Institutes of Health 1F30NS098628 (to MAR).

Conflict of Interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Roy-O’Reilly, M., Ritzel, R.M., Conway, S.E. et al. CCL11 (Eotaxin-1) Levels Predict Long-Term Functional Outcomes in Patients Following Ischemic Stroke. Transl. Stroke Res. 8, 578–584 (2017). https://doi.org/10.1007/s12975-017-0545-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12975-017-0545-3

Keywords

  • Stroke
  • Eotaxin
  • CCLL1
  • Inflammation
  • Neuroinflammation
  • Ischemia